Ocugen, Inc.

Ocugen reported total operating expenses of $17.9 million for Q2 2026 versus $15.2 million in Q2 2025, with R&D of $10.7 million versus $8.4 million and G&A of $7.2 million versus $6.8 million. For the first half of 2026, total operating expenses were $37.3 million versus $31.2 million a year ago, with R&D of $21.9 million versus $17.9 million and G&A of $15.4 million versus $13.2 million. Net loss per common share was $0.07 for Q2 2026 versus $0.05 in Q2 2025. Cash, cash equivalents, and restricted cash were $100.4 million at June 30, 2026, and management said the $130 million convertible notes financing extends runway into 2028. Forward-looking targets included starting OCU410 Phase III in September 2026, OCU410ST interim data in Q3 2026 and top-line data in Q2 2027, and OCU400 top-line data in Q1 2027 with potential approval in Q4 2027; the company reiterated plans to file 3 BLAs by 2028.

Shankar Musunuri framed the quarter as a major validation of Ocugen’s gene-therapy platform, emphasizing that the company is advancing one platform across three late-stage ophthalmology programs rather than three separate drugs. He highlighted the breadth of the target markets, the absence of approved therapies in several of these indications, and said the first half of 2027 should be a catalyst-rich period with top-line data and BLA filings. His tone was confident and strategic, with repeated emphasis on differentiated, one-time treatments and global commercialization potential.

Rita Johnson-Greene focused on operating expenses, reporting $17.9 million of total operating expenses in Q2 2026 and $37.3 million for the first six months of 2026, with R&D making up the majority of spend. She said cash, cash equivalents, and restricted cash totaled $100.4 million at June 30, 2026 after the $130 million convertible notes financing, and stated that the runway extends into 2028. On capital allocation, she said management wants to minimize shareholder dilution while evaluating non-dilutive options such as the OCU410ST PRV, business development deals, and Janus Henderson warrants, while also keeping the option of an equity raise open via an increase in authorized shares.

Analysts focused on ex-U.S. regulatory paths, ArMaDa3 trial design changes, Stargardt pricing, and the timing of rolling BLA submissions. Management said OCU400’s ex-U.S. path is aligned with EMA and other regions and will largely follow the U.S. FDA approval, while ArMaDa3’s smaller 237-patient design was based on updated power calculations using the 31% Phase II effect size and was discussed with FDA. On pricing, management said one-time gene therapies should not be compared directly with chronic therapies and that pricing will depend on data, safety, efficacy, and differentiation. They also clarified that rolling BLA modules for CMC/non-clinical can still be filed ahead of the clinical module, but the PDUFA clock starts only when the clinical section is filed.